CAVNMD (CONTINUOUS ARTERIOVENOUS NON MACHINERY DIALYSIS) TREATMENT OF RENAL FAILURE IN PATIENTS WITH SERIOUS DISEASES

Abstract

The purpose of this study was to evaluate the clinical effectiveness of CAVNMD as treatment for patients with renal failure who can not be treated with the standard dialysis therapies. Twelve patients with renal failure were treated with this new CAVNMD method. We used a dialyzer with a low surface area (<0.6m₂) without the use of pumps for extracorporeal blood circulation. The dialyzing solution was Subrad A solution or Kindaly No. 2 solution diluted 35 times. We perfused a warmed (40°C) dialysate at a rate of 1L per hour. The values of both urea-N and creatinine in the dialysate post dialyzer were the same as those found in blood. The level of blood urea-N was reduced by 25.8% and 42.3%, and tha of serum creatinine by 21.4% and 39.8%, measured at 24 and 48 hours intervals, respectively. After 24 hours, the values of serum potassium decreased to normal in all cases. From 0 to 400ml per hour of fluid could be removed by varying the adjustment. This CAVNMD method proved beneficial for patients with progressive renal failure who cannot undergo standard dialysis therapies.